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ABSTRACT 
TITLE OF THE STUDY : 
HISTOMORPHOLOGY AND ROLE OF IMMUNOHISTOCHEMISTRY  
IN ENDOMETRIAL CARCINOMAS 
 
BACKGROUND: 
Endometrial carcinoma is the 4
th
 most common among the carcinomas in  
women, and accounts for 6% of female cancers with 75% cases occurring in  
postmenopausal women with the peak incidence noted in 55-65 years. Type l 
tumor occurs in the younger age, arise in the background of hyperplastic 
endometrium, are of low grade and has a favorable prognosis and show 
positivity for ER and PR. Whereas Type II carcinomas (serous papillary 
carcinomas and clear cell carcinomas) occurs in the older age, in the 
background of atrophic endometrium, show aggressive behaviour and has poor 
prognosis and are p53 positive.  
However, some cases of morphologically type I endometrioid carcinomas 
may express p53 as that of type II carcinomas and this may have a role in the 
management of the patients.   
  
  
OBJECTIVE: 
To correlate the clinical features and histopathological features of endometrial 
carcinoma, to analyze the spectrum of histopathological features of endometrial 
carcinomas and to correlate the expression of ER, PR and p53 with the 
histopathological grade of endometrial carcinomas.  
 
MATERIAL AND METHODS: 
This is a cross sectional prospective study conducted during October 2012- July 
2014 in the Department of Pathology, Coimbatore Medical College, 
Coimbatore. Thirty cases of endometrial carcinomas were examined 
histomorphologically and correlated immunohistochemically. 
 
RESULTS: 
Thirty cases of endometrial carcinomas were included in the study. The 
incidence of endometrial carcinomas in our hospital was found to be 1.73%. 
The expression of ER in type I carcinomas were 81.25% and in type II was 
21.43%. It was found that there was a positive correlation between the 
expression of ER and type I tumor. The expression of PR in type I carcinomas 
were 75% and in type II 28.75% showed positivity. In the present study, there 
was a positive correlation between the expression of PR and type I tumor. The 
  
expression of p53 in type I carcinomas were 43.75% and in type II 78.57% 
showed positivity. In the present study there was statistical correlation between 
the type II endometrial carcinomas and p53 expression. 
 
CONCLUSION: 
The immunohistochemical study of ER, PR and p53 and its significance 
on the prognosis are few in literature when compared to breast carcinoma. 
Our data will be definitely an important addition to the existing literature. 
 
KEYWORDS: 
 Endometrial carcinoma, immunohistochemistry, ER, PR and p53. 
INTRODUCTION 
Endometrial carcinoma is the 4
th
 most common among the 
carcinomas in women, and accounts for 6% of female cancers with 75% 
cases occurring in postmenopausal women with an average age being 61 
years
1
. Endometrial carcinoma accounts to 150,000 new cases worldwide 
with 7,470 deaths per year
1
. It is the one of the commonest invasive 
carcinoma of the female genital tract constituting 6 cases per 100,000 per 
year with a mortality rate of 2 per 100,000 in India
1
. 
  Usually these carcinoma arises in the postmenopausal women and 
more than 80% present with postmenopausal bleeding. About 2%-14% of 
these carcinomas occur in women younger than 40 years of age. However 
the peak incidence is noted in 55 to 65 years old age group. 
  These neoplasms accounts for 7% of all invasive cancers in women 
excluding skin cancer
2
. It constitutes the second most common 
malignancy in females next to cervical carcinomas. The difference noted 
in epidemiology, presentation and biologic behavior of the endometrial 
carcinomas suggest that there are two fundamentally different pathologic 
types of disease.  
  Endometrial carcinoma  have two basic clinicopathologic forms, 
type I and type II.  
Type I carcinomas occur in the younger age, in the background of 
hyperplastic endometrium. They account for 80-85% of all endometrial 
carcinomas and are generally low grade. They result from unopposed 
estrogenic stimulation and prognosis is generally good with a five year 
survival of 80%. 
 Type II carcinomas are high grade neoplasms which occur in the 
older age in the background of atrophic endometrium and are not related 
to sustained estrogen stimulation. They account for 15%-20% of all 
endometrial carcinomas and occurs in postmenopausal women. They are 
high grade tumours frequently with deeper myometrial invasion and 
increased lymphatic spread.  
Endometrioid carcinoma like any other adenocarcinoma expresses 
pancytokeratins and glycoprotein associated markers CA1254, Ber-EP45,6, 
B72.3
7
. Nearly all endometrioid carcinomas are CK 7 positive and CK20 
negative
6,7
. Unlike other adenocarcinomas, endometrioid adenocarcinoma 
expresses vimentin. Endometrioid adenocarcinoma showing mucinous 
differentiation expresses CEA and COX2
6,7
.   
Type I carcinomas show expression of ER, PR, Bcl2, Beta catenin 
and PTEN whereas, type II carcinomas (uterine papillary serous, clear 
cell carcinomas) show  immunopositivity for p53, p16 and Ki67 and 
usually do not express ER and PR. 
   In Type l carcinomas, ER and PR will be positive and the 
treatment consisting of hysterectomy along with hormonal therapy  will 
be sufficient, whereas Type II carcinomas (since the tumor is aggressive) 
are usually p53 positive and are aggressive and hence these patients along 
with hysterectomy, needs chemotherapy and radiotherapy and further 
follow up.  
However some cases of morphologically type I endometrioid 
carcinomas may express p53 as that of type II carcinomas and this may 
have a role in the management of the patients.   
In our study, the histomorphology of endometrial carcinomas are 
correlated with immunohistochemistry using the panel of markers 
constituting ER, PR and p53. 
  
  
 
 
 
 
 
 
 
 
 
Aim and Objectives 
  
AIM OF THE STUDY 
 
               The aim of this study is to study the spectrum of 
histomorphology of endometrial carcinomas with special reference to 
immunohistochemical findings including ER, PR and p53 
OBJECTIVES 
 
1.  To correlate the clinical features and histopathological features of 
endometrial carcinoma.         
2.  To analyze the spectrum of histopathological features of 
endometrial carcinomas. 
3.  To correlate the expression of ER, PR and p53 with the 
histopathological types  of endometrial carcinomas.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Review of Literature 
  
REVIEW OF LITERATURE 
Primary endometrial carcinomas constitute a range of 
morphologies including carcinomas closely resembling endometrial 
epithelium  (endometrioid) , clear cell carcinomas, uterine papillary 
serous carcinomas, and carcinomas sharing one or more of these features, 
undifferentiated carcinomas and tumours with mixed epithelial - 
mesenchymal differentiation. 
Anatomy of uterus 
 The uterine cavity is a hollow, pear shaped organ weighing    40-
80 grams and measuring approximately 8X5X4 cms
8
.                     
 
Figure.1: Anatomy of the uterus 
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The uterine cavity is lined by endometrial mucosa constituting the 
endometrium which is highly specialized active layer responding to 
cyclic ovarian hormones and is essential for menstrual and reproductive 
function.  
 
The middle layer is the thick muscular layer, the myometrium 
which is formed primarily of smooth muscle cells and the serosal 
covering, enveloping the uterus
9,
.   
 
Figure 2 : Histology of uterus 
 
ENDOMETRIUM 
MYOMETRIUM 
Embryology of female genital tract: 
The development of the uterus is complex. Approximately until the 
8
th
 week of the gestation, the primordial ie the mesonephric ducts and 
paramesonephric ducts exist simultaneously. The differentiation of the 
sex involves multiple steps in which hormonal signals, growth factors and 
specific genetic influences are required. 
 
 In the females, absence of Y chromosome and lack of testosterone 
exposure causes the fusion and canalization of the paramesonephric ducts 
in the midline and forms the female pelvic organs
10
. 
 
UTERINE CYCLE
11 
The uterine corpus is divided into the uterine cavity and the cervix. 
The uterus consists of an inner endometrial layer, outer muscular 
myometrium and a serosal covering. The lining of the epithelium is 
simple columnar forming glands, separated by stromal cells. 
The endometrium is formed of two layers, the stratum functionalis 
and stratum basalis. The stratum functionalis is further divided into 
superficial stratum compactum and the deep stratum spongiosum. The 
stratum spongiosum has maximal secretory activity and unresponsive 
stroma while the stratum compactum responds remarkably to hormonal 
stimulation with a prominent predecidual reaction and numerous 
granulocytes with less secretory activity. The basalis consists of tubular 
glands and compact stroma with no secretory or mitotic activity in these 
glands.  
The junction between the endometrium and the endocervical 
epithelium consists of the isthmic endometrium. The glands in the isthmic 
endometrium are typically flattened and slit like, lined by an epithelium 
containing a mixture of columnar cells and ciliated cells with more 
fibrous stroma. 
 
THE MENSTRUAL CYCLE
11
 
The bleeding from the secretory endometrium is associated with  
ovulatory cycle, which, does not exceed a length of 5 days is defined as 
normal menstrual cycle
12
.  
The menstrual cycle has two main phases, the proliferative phase 
and the secretory phase. 
 
 
 
The normal proliferative phase
13 
 
This phase lasts two weeks under physiological conditions, 
fluctuating between ten and twenty days. In the early phase the 
endometrium is thin with sparse non-budding, non branching glands and 
a loose stroma of spindle cells. At about 8-10 days, an increase in 
endometrial thickness as a result of stromal edema which peaks at day 
ten, is noted.  
 
In the preovulatory period as the estrogen level decreases, the 
stromal edema comes down and is followed by the continuous
 
growth of 
the glands which is seen to be lined by tall columnar cells with basophilic 
cytoplasm. The nuclei becomes  pseudostratified and ovoid with coarse 
chromatin. The endometrial stroma is densely
 
cellular with small and oval 
cells, with small dark staining nuclei and indistinct cytoplasm. Mitosis is 
frequent.      
 
In the late proliferative phase the glands will have increased 
tortuosity and variability, with less mitotic activity. Subnuclear vacuoles 
and
 
stromal edema starts to appear.
 
 
  The secretory phase14,15. 
Around the 14
th
 day of the cycle, ovulation occurs. In the first and 
second day of post ovulatory day, the endometrial glands becomes larger, 
less basophilic because of the interruption of the pseudostratified 
epithelium by vacuoles. 
 
Early secretory phase: 
This phase which lasts from day fifteen to nineteen is heralded by 
the appearance of the subnuclear vacuoles. The basal vacuoles will push 
the nuclei to the middle of the cell creating a piano key like appearance. 
At seventeenth day, there are uniform subnuclear vacuoles. The vacuoles 
move toward the lumen on  eighteenth day and on the nineteenth day, the 
nuclei migrates to the base again. No mitotic activity is seen. 
 
Mid secretory phase: 
This phase lasts from day nineteen to day twenty five. There is 
secretory exhaustion seen in this phase. At day twenty, there is a peak in 
the intraluminal secretions. On day twenty one, there is increased stromal 
edema with prominent spiral arterioles. Stromal edema is at its peak on 
day twenty two. By day twenty three, the edema decreases and the 
stromal predecidualisation commences.  
On day twenty four, the predecidua extends to bridge the vascular 
elements.  
 
Late secretory phase: 
       This phase is from day twenty six to twenty eight and shows 
extension of the predecidual change from the surface lining downward 
deep into the stratum compactum. On day twenty seven, numerous 
granulated lymphocytes appear. In the central spongy part of the 
endometrium the glands have a characteristic sawtooth appearance. 
 
Menstrual phase
16 
     If pregnancy has not occurred the late secretory phase leads to 
menstrual phase, starting fourteen days after ovulation. Histologically 
there will be crumbling of the stroma and glandular collapse and 
hemorrhage in the superficial stroma.  
The stromal cells form tightly clustered ball and separate from the 
glands , which will have an unusually deep blue colour and overlying 
epithelial cells appear degenerative 
 POSTMENOPAUSAL ENDOMETRIUM
12 
After the ovary stops producing estrogen and progesterone the 
endometrium is no longer stimulated and hence undergoes atrophy. The 
postmenopausal endometrium is usually thin and inactive though there 
may be changes in the thickness. 
 The glands become small and scant and are lined by cuboidal or 
flattened cells and often are unevenly distributed throughout the tissue. 
The stroma becomes fibrous and the cells of the stroma lose their 
cytoplasm and appear acellular.  
 
Another pattern of post menopausal endometrium is the cystic 
atrophy which consists of cystically dilated glands which are lined by 
flattened epithelium and the lumen contains partly non-specific secretions 
and partly transudate.  
 
DISORDERED PROLIFERATIVE ENDOMETRIUM
12,15,17,18
: 
 
Prolonged proliferation of endometrium due to anovulation gives 
rise to disordered proliferative endometrium. It is an intermediate 
between normal proliferative and benign hyperplastic endometrium. The 
patient usually presents with irregular uterine bleeding.  
 
It is characterized by cystically dilated endometrial glands which 
are distributed irregularly with patchy stromal breakdown, resulting from 
focal thrombosis. Tubal metaplasia of endometrial glands is also 
common. 
 
ENDOMETRIAL EPITHELIAL METAPLASIA
12,15
: 
The change in cellular differentiation of one type of epithelium into 
another type of epithelium which is not present in the normal 
endometrium is defined a endometrial metaplasia. Some of the most 
common forms are squamous, mucinous or ciliated. 
Squamous metaplasia 
This occurs in benign reactive process and carcinoma. Few causes 
associated with benign changes are chronic endometritis, intrauterine 
device and trauma.  
Two types of squamous metaplasia are seen. 
A) Typical squamous metaplasia 
B) Morular metaplasia. 
 
 
Typical squamous metaplasia: 
This occurs in scattered areas. The term icthyosis uterus is 
described as when whole of the endometrium is extensively replaced by 
squamous epithelium. It is associated with cervical obstruction and 
chronic inflammation.  
Morular metaplasia: 
Morular metaplasia is seen as cohesive small, round, granuloma 
like aggregates of squamous cells located in-between the glands. These 
morules may enlarge to form sheets with radially arranged glands around 
the periphery.  
At times the morular metaplasia is seen associated with some 
degree of glandular crowding wherein endometrial intraepithelial 
neoplasia and nearby adenocarcinoma has to be ruled out. 
Mucinous metaplasia: 
Mucinous metaplasia is characterised by glands of the 
endometrium being lined by cuboidal or columnar epithelium with 
prominent intracytoplasmic mucin.  
There are three types of mucinous metaplasia: 
 
i. Type A – The glands in this type are lined by endocervical like 
cuboidal epithelium usually presenting in perimenopausal women. 
 
ii. Type B – This type is characterized by architectural complexity 
and pseudopapillary pattern. 
 
iii. Type C – In this type the glands of the mucinous epithelium are 
arranged in cribriform pattern or are seen to exhibit microglandular or 
villoglandular pattern. This is associated with significant risk of 
adenocarcinomas. 
 
Ciliated or tubal metaplasia: 
This type of epithelium is characterized by columnar epithelium 
which is lined by cilia with clear round cells seen in-between the cells 
and are normally found in proliferative phase. 
 
Clear cell metaplasia: 
In this type, the epithelial cells have abundant clear cytoplasm 
which is easily confused with clear cell carcinoma. 
 
 
 
Features favoring clear cell metaplasia are: 
a) The glands of the endometrium should have normal architecture 
and distribution. 
b) Bland nuclear features.  
c) Metaplasia in focal areas. 
d) Grossly there should not be any visible tumor. 
e) There should not be stromal invasion. 
f) There should be strong positivity for Estrogen receptor. 
Hobnail metaplasia: 
This rare type is characterized by cells with rounded nuclear 
protrusion beyond the cytoplasmic borders. It is often associated with 
Arias stella reaction  and is caused by degenerative changes associated 
with necrosis and exfoliative artifact. 
Eosinophilic metaplasia: 
In this type, the glands are lined by cells which have granular 
eosinophilic cytoplasm because of the presence of increased 
mitochondria.  
 
 
Other non epithelial metaplasia 
Some endometrial mesenchymal metaplasia includes cartilaginous and 
osseous metaplasia, smooth muscle metaplasia, glial metaplasia and 
extramedullary hematopoiesis. 
 
ENDOMETRIAL POLYPS: 
Endometrial polyps are defined as polypoidal structure with benign 
glands and stroma. It can be sessile or pedunculated. The polyps in the 
endometrium are one among the frequent causes of abnormal uterine 
bleeding and are commonly found in patients in women of the 
reproductive age group, postmenopausal women and in patients with 
hormonal replacement therapy and tamoxifen therapy.  
Microscopically, there are abnormally dilated glands lined either 
by atrophic epithelium, or by poorly developed secretory epithelium or 
proliferative epithelium in a fibrous stroma. The stroma characteristically 
contains thick walled blood vessels and sometimes the ectatic vessels. 
The polyp are divided into  
a) Hyperplastic polyp. 
b) Atrophic polyp. 
c) Functional polyp. 
ENDOMETRIAL HYPERPLASIA 
DEFINITION
19 
Endometrial hyperplasia is defined as a proliferating endometrium 
with glandular architectural abnormalities resulting in either cystically 
dilated glands (simple hyperplasia) or crowded  glands (complex 
hyperplasia). 
Endometrial hyperplasia occurs as a consequence of  
a) High levels of estrogen for a long period. 
b) Repeated anovulatory cycles. 
c) Ovarian neoplasms secreting estrogen. 
d) Increased levels of estrogen due to peripheral conversion of 
androgen. 
The hyperplastic endometrium is white to tan tissue that may be 
seen as diffuse thickening or polyp like lesion. 
Various classifications of endometrial hyperplasia: 
Tavassoli and Krauss (1978)
20 
classified endometrial hyperplasia  as 
a) Cystic hyperplasia, 
b) Adenomatous hyperplasia, 
c) Atypical hyperplasia. 
Ronnett B.M and Robert J.Kurman (2004)
19
 classified endometrial 
hyperplasia as 
1. Hyperplasia without cytologic atypia (non atypical hyperplasia) 
a) Simple, 
b) Complex. 
2. Hyperplasia with cytologic atypia (atypical hyperplasia) 
a) Simple, 
b) Complex. 
According to WHO classification17 
1. Hyperplasia without atypia 
a) Simple hyperplasia without atypia 
b) Complex hyperplasia without atypia 
 
2. Atypical hyperplasia  
a) Simple atypical hyperplasia 
b) Complex atypical hyperplasia 
 
 
HYPERPLASIA
14,17,18,19
 
Simple hyperplasia without atypia: 
This is characterized by mild increase in gland to stromal ratio. The 
glands are round and tubular, exhibiting marked variation in size and 
shape. The cells in the glands are pseudostratified. It has oval nuclei with 
dispersed chromatin and inconspicuous nucleoli. The stroma is cellular as 
in proliferative phase. Mitotic figures and apoptotic bodies are noted. 
There is 1% chances of these lesions progressing to adenocarcinoma. 
Complex hyperplasia without atypia: 
In this type the glands show over crowding and budding. The 
polarity and the pseudostratification of the cells are maintained. Mitotic 
activity is <5mitosis per 10 high power field. Apoptotic bodies may be 
frequently encountered. Approximately 3% of these lesions progresses to 
adenocarcinoma. 
 
Atypical hyperplasia: 
In atypical hyperplasia, the cells appear paler and are   
characterized, cytologically, by the presence of stratification of cells with 
round vesicular nuclei and slightly prominent nucleoli.  
Simple hyperplasia with atypia:  
It has similar architectural features as that of simple hyperplasia in 
addition they show stratification of cells with round vesicular nuclei and 
slightly prominent nucleoli. Approximately 8% of these lesions 
progresses to carcinoma. 
Complex hyperplasia with atypia: 
This type is similar to that of complex hyperplasia, in addition they 
show stratification of cells with round vesicular nuclei and slightly 
prominent nucleoli. There are about 25% chances for these lesions 
turning into carcinoma.   
ENDOMETRIAL INTRAEPITHELIAL NEOPLASIA
12,15,17
 
Endometrial intraepithelial neoplasia is described as monoclonal 
proliferation of endometrial glands which are altered cytologically and 
architecturally. The rate of  transformation into type I endometrioid 
adenocarcinoma is 26-37% and intraepithelial carcinoma in type II 
carcinomas arise instantly without preceding hyperplasia or atypia as in 
type I carcinomas. 
 
The features of EIN include: 
 a) The crowded glands are lined by columnar epithelial cells with   
rounded non-stratified nuclei or elongated pseudostratified nuclei 
with clumped smudged chromatin and prominent nucleoli.  
b)  Absence of stromal invasion. 
 
c) The size of the intraepithelial lesion should be greater than 1mm. 
ENDOMETRIAL ADENOCARCINOMA
12,15,17,21 
Endometrial adenocarcinomas usually arise in postmenopausal 
women and account for 80% of the postmenopausal bleeding. 
Carcinomas of the endometrium are broadly classified into following two 
types: 
Estrogen dependent type I tumors and non estrogen dependent type 
II tumours. 
Type I tumors are usually seen in premenopausal and 
perimenopausal women in patients with hyperplastic endometrium, and  
usually does not invade the myometrium at earlier stages. 
 Most of them are well to moderately differentiated and rarely 
presents with distant metastasis and hence usually have a better 
prognosis. 
 Whereas type II tumours are usually seen to occur in females little 
older than type I. Type II tumours, are usually of higher grade and 
presents with distant metastasis and are associated with poor prognosis.  
 
RISK FACTORS FOR DEVELOPING ENDOMETRIAL 
CARCINOMA: 
1. Estrogen 
2. Tamoxifen therapy 
3. Polycystic ovary syndrome 
4. Obesity 
5. Reproductive factors 
 
Estrogen: 
Both the exogenous and endogenous estrogen play a significant 
role in tumors genesis.  The patients who are at risk of developing 
carcinoma from exogenous exposure to estrogen are: 
a)  Women taking oral contraceptive pills sequentially, 
b)  Postmenopausal women who are receiving estrogen replacement 
therapy, 
c)  Women with ovarian dysgenesis who had received estrogen 
therapy during   puberty. 
 
The patients on endogenous estrogen are: 
a)  Patients with granulosa cell tumour of the ovary or theca cell 
tumour of the ovary., 
b)  Women with anovulatory cycles., 
c)  Postmenopausal women who were obese., 
d)  Women suffering from liver disease
22
. 
 
Tamoxifen:  
Tamoxifen is used in the treatment of breast cancer has been 
associated with two to three times increase risk of endometrial 
carcinoma
24
. 
 
Obesity: 
Obesity is one among the significant risk factor in endometrial 
cancer
25
. Body mass index of ~ 30kg/m
2
 or higher has elevated risk of 
endometrial carcinoma.  
Polycystic ovarian syndrome: 
Also known as ovarian hyperandrogenism is generally associated 
with chronic anovulation and progesterone deficit.The risk of endometrial 
cancer in these patients is about 5%
26
. 
Reproductive and other factors: 
Early menarche and late menopause exposes the individual to 
increased risk of carcinoma due to increase in duration of exposure to 
estrogen. Nulliparity and infertility are associated with anovulation and 
progesterone insufficiency. 
 Granulosa cell tumour, thecoma, polycystic ovary disease and 
hyperthecosis are associated with prolonged exposure of estrogen.  
 
 
 
 
WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF 
THE UTERINE CORPUS
27 
 
 
I.  Epithelial carcinoma
 
i. Endometrioid adenocarcinoma  
ii. Variant with squamous differentiation  
iii. Villoglandular variant  
iv. Secretory variant  
v. Ciliated cell variant  
vi. Mucinous adenocarcinoma 
vii. Serous adenocarcinoma  
viii. Clear cell adenocarcinoma  
ix. Mixed cell adenocarcinoma 
x. Squamous cell carcinoma 
xi. Transitional cell carcinoma 
xii. Small cell carcinoma  
xiii. Undifferentiated carcinoma 
xiv. Others. 
 
 
ENDOMETRIOID ADENOCARCINOMA
19
: 
GROSS FEATURES: 
Grossly the size of the uterus may be normal , small atrophic or 
slightly enlarged. The cut surface may show diffuse thickening of the 
endometrium or it can also present as single mass or two – three separate 
masses. Usually the tumour has raised rough shaggy surface with 
ulceration, occupying atleast half of the surface area of the endometrium. 
The myometrial invasion may or may not be present depending upon the 
stage of the tumour. 
 
MICROSCOPY: 
The cellular features generally resembles proliferative 
endometrium with a complicated architecture including solid growth, 
villoglandular pattern, cribriform like growth or maze like interconnected 
lumen. The individual epithelial cells are large, with nuclear stratification, 
coarse clumped chromatin and prominent nucleoli. Tumours may be seen 
associated with focal differentiation to squamous, mucinous or tubal 
epithelium.  
 
 
The endometrial adenocarcinoma usually spread centrifugally into 
the stroma. A diagnosis of myoinvasion is made when the malignant 
glands have transgressed the endo-myometrial junction into the 
underlying muscular uterine wall. 
 
International Federation of Gynaecology and Obstetrics (FIGO) 
grading recommended by WHO: 
 
ARCHITECTURAL GRADING: 
Grade 1 – 5% or less of non squamous solid growth . 
Grade 2 – 6-50% of non squamous solid growth. 
Grade 3 – 50% or more of non squamous growth. 
 
CYTOLOGICAL GRADING
19 
Grade 1 –  oval nuclei ,with mild enlargement and evenly dispersed  
  chromatin. 
Grade 2 –  intermediate between grade 1 and grade 3. 
Grade 3 –  markedly enlarged pleomorphic nuclei with irregular coarse 
chromatin  and prominent eosinophilic nucleoli. 
To note: Cytological features are used in formulating the final grade. 
a) Tumours with low architectural grade but having higher 
                    
 cytological grade should be regarded as high grade tumour. 
  
b) Nuclear grade takes primacy over the architecture in serous 
adenocarcinomas and clear cell adenocarcinomas. 
Low grade carcinoma
19
: 
Tumours in this grade consists of <5% of solid growth pattern 
characterized by irregular and larger malignant glands lined by columnar 
cells. There are many variants in this category which includes secretory 
variant, villoglandular variant, endometrioid adenocarcinoma with 
squamous, mucinous or tubal differentiation. 
Intermediate grade carcinoma: 
In this grade tumour constitutes 6-50% of solid growth pattern 
characterized cytologically by high degree of nuclear 
pleomorphism,(ie)three to four times the variation in nuclear size and 
more coarse clumped chromatin. 
High grade carcinoma
19
: 
This grade of tumour consists of solid growth exceeding 
50%.These tumours include high grade type I endometrioid carcinomas, 
serous carcinomas and clear cell carcinoma (type II), neuroendocrine 
carcinomas and undifferentiated carcinomas.  
 
 VARIANTS OF ENDOMETRIAL CARCINOMA
19 
Endometrial carcinoma with squamous differentiation
21
: 
 Numerous morphologic forms of endometrial adenocarcinoma 
have been described. Some, such as adenoacanthoma, adenosquamous 
carcinoma, secretory carcinoma, and ciliated carcinoma, are thought to 
represent variants of ordinary type I (‘endometrioid’) adenocarcinoma. 
Others, notably papillary serous carcinoma, clear cell carcinoma, and 
mucinous adenocarcinoma, are usually without squamous component 
regarded as being  high grade type II , although a tumour can have mixed 
types. 
Adenoacanthoma is the term traditionally given to the well-
differentiated endometrioid adenocarcinoma containing similarly well-
differentiated (benign-appearing) squamous elements derived from 
metaplasia of the tumor glands . 
Adenosquamous (mixed) carcinoma refers to the endometrioid 
carcinoma containing malignant appearing squamous elements.Patients 
with adenosquamous carcinoma are said to have a worse prognosis than 
those with adenocarcinoma or adenoacanthoma. However, several studies 
have shown that, stage by stage and grade by grade, there are no 
prognostic differences between pure adenocarcinoma, adenoacanthoma, 
and adenosquamous carcinoma.  
In other words, once an endometrial adenocarcinoma is clinically 
staged and microscopically graded into well-differentiated, intermediate, 
and poorly differentiated categories, the presence and appearance of a 
focal squamous component would seem immaterial.  
 
Morphologic studies have suggested – and immunocytochemical 
studies have supported – the notion that adenoacanthoma and 
adenosquamous carcinoma represent a spectrum of squamous metaplasia 
in a single tumor type rather than two independent entities.
 
Endometrial adenocarcinoma - villoglandular variant: 
This variant is similar to villoglandular adenocarcinoma arising 
from the endocervix and is characterized by slender long delicate papillae 
lined by well differentiated tumour cells and this pattern can be seen in 
typical endometrial type (type I) or may be entirely papillary
29
 and should 
not be confused with type II serous papillary carcinoma. Cytologically 
they resemble grade I carcinoma. 
 
Endometrial adenocarcinoma with ciliary cell differentiation
28,30
:        
          Ciliated cells are usually uncommon but can be encountered. A 
minimum of 75% of the cells should be ciliated to consider it as ciliated 
cell adenocarcinoma. They usually have a good prognosis. 
 
Endometrial carcinoma with secretory differentiation: 
This variant resembles glands of early or mid secretory 
endomerium
28
.The changes in this variant are subnuclear and 
ssupranuclear vacuolation. It is associated with good prognosis.  
 
MUCINOUS ADENOCARCINOMA: 
 Mucinous adenocarcinoma is a tumor subtype characterized by 
abundant mucin secretion. It is distinguished from mucinous metaplasia 
by virtue of its architectural and cytologic atypia. It should be noted that 
scattered foci of mucin positivity are often found in ordinary endometrial 
adenocarcinoma. The distinction between endometrial mucinous 
adenocarcinoma and primary endocervical adenocarcinoma cannot be 
made on the basis of morphologic or histochemical features. 
Immunohistochemically, most uterine mucinous adenocarcinomas are 
reactive for CK7 but not for CK20 or CDX2. 
Grossly it resembles endometrioid adenocarcinoma with secreted 
tenacious mucous. In microscopy the cells are tall with basal nuclei and 
prominent intracytoplasmic mucin which involves atleast half of the 
cells
35
.  
Periodic acid Schiff, alcian blue and mucicarmine are all useful 
stains to identify mucin. 
SEROUS ENDOMETRIAL INTRAEPITHELIAL CARCINOMA: 
The precursor of serous adenocarcinoma of endometrium is 
endometrial intraepithelial carcinoma
36,37
.  It occurs in postmenopausal 
age group in a background of atrophic endometrium. The atrophic 
endometrium shows abrupt transition where highly pleomorphic cells 
with severe nuclear atypia and high mitotic activity without stromal 
invasion replacing the endometrial surface glands. The cells express 
strong p53 immunoreactivity and loss of ER and PR
37
. 
SEROUS ADENOCARCINOMA (Type II) : 
This is an aggressive form of endometrial carcinoma constituting 
1-10% of all endometrial cancers. It occurs in older age group ie 4-10 
years older than women with endometrioid carcinoma (type I). These 
patients have history of having been received estrogen therapy and also 
lack hyperplasia or previous or concurrent endometrial intraepithelial 
neoplasia
38
 of endometrioid type I cancer. 90% of the patients are parous, 
10% are obese or have diabetes
39
. Grossly they appear as bulky  necrotic 
masses
37
.  
On microscopy the tumour cells are arranged in branching papillae 
exhibiting nuclear stratification forming tufts which detaches freely. The 
papillae  are often irregular and are lined by polygonal cells with large 
pleomorphic, hyperchromatic nuclei containing macronucleoli. These 
tumours show an increase in mitosis when compared to type I 
endometrial cancers.       
In about one third of the cases psamomma bodies are seen40. The 
tumour invades the myometrium commonly with granulation tissue type 
of response at the invasion site.  
In 80-90% of the serous carcinomas p53 mutation is encountered. 
Immunohistochemistry shows diffuse and intense nuclear staining 
involving almost all tumours cells
41,37
. ER and PR are absent or only 
weakly expressed in most tumors
42
. 
 
CLEAR CELL ADENOCARCINOMA
28
: 
This tumour comprises of about 1-6% of all endometrial 
endocarcinoma and is a prototype of type II endometrial carcinoma. The 
mean age is 65-69 years. It is less associated with obesity, diabetes and 
hormone replacement therapy. There are various patterns that include 
papillary, tubulocystic and solid. Among the various patterns, the 
papillary pattern is common.  
On microscopy the tumour cells arranged in small rounded papillae 
with hyalinised fibrovascular cores. The papillae and tubules are lined by 
hobnail cells with the nucleus, bulging into the lumen with prominent 
clear cytoplasm, because of the presence of glycogen or may display 
oxyphilic cytoplasm.  
A frequent and characterisctic of this tumour is intracytoplasmic 
hyaline bodies. The lumen of the tubules and cysts may contain mucin. 
The tumour cells will have pleomorphic nuclei with  prominent nucleoli 
and frequent mitotic figures.  
Immunohistochemically, unlike the type I tumors they are negative 
for ER and PR and unlike type II tumors , they are p53 negative. 
 
MIXED ADENOCARCINOMA
41
: 
This adenocarcinoma consists of mixture of type I endometrioid 
adenocarcinoma or their variants and type II carcinoma. The minor 
component should constitute 10% of the neoplasm. The prognosis of the 
tumor depends on the quantity of the most aggressive component. 
MALIGNANT MESODERMAL (MULLERIAN) MIXED 
TUMOUR(CARCINOSARCOMA): 
These tumours constitute less than 5% of endometrial carcinoma. 
Factors which are associated with this type of tumour are body weight, 
exogenous estrogen, nulliparity, tamoxifen therapy and pelvic irradiation.  
Grossly the tumour presents as polypoidal, necrotic, fleshy and 
hemorrhagic mass occupying the uterine cavity with extensive 
involvement of the myometrium. 
On microscopy the tumour is composed of dual population of 
cells.The epithelial component can be endometrioid, squamous, 
mucinous, clear cell and undifferentiated. The mesenchymal component 
can be homologous such as fibrosarcoma, stromal sarcoma and 
leiomyosarcoma. The tumor has the worst prognosis.  
 
UNDIFFERENTIATED CARCINOMA: 
Undifferentiated carcinoma are those that lack any evidence of 
differentiation after extensive sampling. It constitutes less than 2% of 
endometrial tumours
35
. On microscopy the cells are pleomorphic with 
prominent nuclear atypia. The prognosis is poor. Few other types of 
endometrial carcinomas are transitional cell carcinoma, squamous cell 
carcinoma and small cell carcinoma.  
METASTATIC CARCINOMA 
Metastatic carcinoma of endometrium is to be suspected if one or 
more of the following features are present. 
1. A tumour with an unusual macroscopic and histological pattern for 
primary. 
2. Diffuse displacement of the endometrial stroma by the tumor cells. 
3. Lack of premalignant changes in endometrial glands. 
 
Most common tumors which metastasizes are breast carcinoma, 
stomach carcinoma followed by melanoma, lung, colon, pancreas 
and kidney19. 
 
STAGING OF ENDOMETRIAL CARCINOMA- 
INTERNATIONAL FEDERATION OF GYNAECOLOGISTS AND 
OBSTETRICIANS
15
  
Stage 1   -   Tumour that is confined to uterus 
1a:  The tumour which does not invade the myometrium  or 
invades less than half of the myometrium. 
1b : The tumour which invades half and more than half of the 
myometrial wall. 
 Stage II -  The  tumour invading the stroma of the cervix but not  
extending beyond the uterus. 
Stage III –  Tumour extending outside the uterus 
       IIIa – Tumour involving the serosa and / or adnexa . 
       IIIb – Directly extending or metastasizing to the vagina and  
   Parametrium. 
       IIIc1 – Positive Pelvic lymph node metastasis. 
       IIIc2 –  Positive para aortic lymph nodes with or without  
positive pelvic lymph nodes.  
Stage IV 
IVa –  Tumour invading into the mucosa of the bladder and or 
mucosa of the bowel. 
IVb –  Metastasis to distant sites including intraabdominal 
metastases and or inguinal lymph nodes.. 
MYOMETRIAL INVASION: 
Myometrial invasion is in the form of jagged, irregular branching 
glands surrounded by granulation tissue.  
VASCULAR AND LYMPHATIC INVASION: 
Vascular invasion appears to be an independent prognostic factor. 
Its presence even in the early stage well differentiated endometrioid 
carcinoma (type I ) appears to be associated with greater- risk of 
recurrence and poor prognosis
9
. 
Following are the pitfalls in identifying vascular / lymphatic invasion: 
a) The presence of contaminants / floaters in vascular spaces. 
b) The intraoperative use of uterine manipulator in cases of 
laparoscopically obtained hysterectomy leading to pseudovascular 
invasion. 
c) The vascular / lymphatic invasion by histiocyte like cells. 
Cervical involvement: 
Tumours with extension into the cervical epithelium are considered 
as stage I with good prognosis and if there is invasion of the cervical 
stroma the prognosis is poor and is considered as stage II
43
. 
Peritoneal washing cytology in endometrial carcinoma: 
Peritoneal washings are collected in saline at the time of surgery 
and processed immediately to avoid artefacts and degeneration of the 
cells. Positive peritoneal washings for endometrioid type (type I) of 
endometrial carcinoma constitutes single tumor cells and three 
dimensional clusters of tumor cells. Individual cells have enlarged nuclei, 
coarse chromatin and prominent nucleoli with scant to moderate amount 
of cytoplasm. 
Yanoh et al found that endometrial carcinoma and positive 
peritoneal cytology exhibiting high cellularity, scalloped edges of cell 
clusters and isolated cells were associated with the presence of intra 
abdominal macroscopic metastatic lesion. 
Papillary serous carcinomas and clear cell carcinomas (type II) are 
among the aggressive tumors and are characterized cytologically by 
marked nuclear pleomorphism, prominent nucleoli and abnormal mitoses. 
It has been reported that upto 4.1% of cases with positive peritoneal 
cytology recurred
44
.  
PROGNOSTIC FACTORS: 
a) The stage of the disease, 
b) The histological architecture, 
c) The cytological grade, 
d) The invasion of the myometrium, 
e) The involvement of the cervix, 
f) The involvement of the adnexa, 
g) The lymphovascular involvement, 
h) The positive peritoneal cytology. 
Other prognostic factors include DNA ploidy, diploidy being 
associated with higher disease free survival. Immunohistochemical 
staining for ER, PR, p53 and Ki67 has been suggested as important 
parameters in assessing the prognosis in endometrial carcinomas. Finally 
a number of molecular alterations have also been proposed as putative 
prognostic factors for endometrial carcinoma including assessment of 
microsatellite instability and alterations in PTEN and B- catenin. 
 
IMMUNOHISTOCHEMISTRY 
 ESTROGEN AND PROGESTERONE RECEPTORS 
45,46
 
Estrogen receptor (ER) constitutes a group of receptors which 
gets activated by 17β-estradiol (estrogen). It is one among the nuclear 
hormone receptor. The family of ER has two groups of receptors, 
intracellular receptors (ER), and the estrogen G protein coupled receptor 
GPR30 (GPER). The main function of the ER is as a DNA binding 
transcriptional factor that regulates the expression of gene. 
 
Along with additional functions which are independent of binding 
of the DNA
19. 
Because there is alternative RNA splicing, there appears to 
be several nuclear isoforms of ER. At least three ER alpha and five ER 
beta isoforms
 
have been identified. The ER beta isoforms receptor 
subtypes will transactivate transcription when there is a heterodimer 
along with the functional ERß1 receptor. The ERß3 receptor appears to 
occur at high levels in the testis. The other two  ER alpha isoforms were 
36 and 46kDa
47,48.. 
 
Both these forms of ERs are expressed in various tissue types; but 
there appears to be some  differences in their pattern of expression.In the 
breast cancer cells,stromal cells of the ovary,in the endometrium and in 
the hypothalamus ER alpha forms were found. The ERβ protein was seen 
to be expressed in the brain, heart, bone, kidney, intestinal mucosa, lungs, 
endothelial cells and in the prostate
45,49
 . The ERs were regarded as 
cytoplasmic receptors in the unliganded state, but visualization research 
observed a fraction of the ERs located in the nucleus
50
. Different ligands 
have varying affinity for the alpha and the beta isoforms of the ER. 
 
• 17-beta-estradiol appears to bind to both the receptors, 
• Estrone specifically binds to the alpha receptor, 
• Estriol binds preferentially to the beta receptor, 
 
The subtypes of selective estrogen modulators tends to bind to 
either the alpha or beta- subtype. Also, the combinations of different 
estrogen receptor might respond differently to the various ligands 
translating them to tissue selective agonistic and antagonistic effects. The 
ratio of alpha to the beta- subtype concentration appears to play certain 
role in some disease
51,52. 
 
The principle of  the selective estrogen receptor modulators is  
based on its ability to promote the interactions of ER with various 
proteins like the transcriptional coactivator or co repressors. The ratio of 
coactivator to co repressor protein appears to be different in various 
tissues
53
.  
 
The result of which is, the same ligand may act as an agonist in 
some tissue (where there is predominance of coactivators ) while 
antagonistic in the other tissue (where there is corepressors domination).  
For example, tamoxifen which is an antagonist in breast
54 
and is used in 
treatment of breast carcinomas also acts as an ER agonist in bones  
preventing osteoporosis and also acts as partial agonist in the 
endometrium exposing to endometrial carcinomas.
55. 
 
The progesterone receptor (PR) also known as NR3C3 a nuclear 
receptor subfamily 3, group C, member 3, is an intracellular steroid 
receptor that preferentially binds to progesterone. There are two main 
forms, A and B differing in their molecular weights. PR-A and PR-B are 
simiilar in sequence, except that PR-A appears to lack 164 amino acids at 
the N-terminus, forming the shortest of the two proteins
46,56. 
 
Estrogen appears to be important to induce the progesterone 
receptors. When there is no binding hormone , the carboxyl terminal 
inhibits transcription process. The hormone binds   and induces a 
structural change removing the inhibitory action.Progesterone is an 
important regulator of normal female reproductive function, with various 
tissue-specific effects
51. 
 
The physiological effects of progesterone appears to be dependent 
completely on the presence of the human progesterone receptor (hPR), 
which is a member of the steroid receptor.Progesterone has a numerous 
physiological effects amplified in the presence of estrogen. Estrogen 
along with the estrogen receptors causes up regulation of the expression 
of progesterone receptors
57,59
. 
 
The functions of progesterone through its receptors appears to be 
important in the reproductive system. Progesterone is  known as the 
"hormone of pregnancy",and appears to be important  in the development 
of the fetus
58.
 Progesterone prepares the uterus for implantation by 
causing thickening of the vaginal epithelium and cervical mucus, making 
it  impermeable to sperm. If there is no pregnancy, the levels of 
progesterone levels decrease, leading to  bleeding. Normal menstrual 
bleeding occurs when there is withdrawal of  progesterone
30 
 
When implantation occurs, progesterone decreases the maternal 
immune response allowing the pregnancy. Progesterone decreases the 
contractility of the uterine smooth muscle and also causes inhibition of  
lactation during pregnancy. The decrease in levels of progesterone after 
delivery is one of the triggers for milk production, and also the fall in 
progesterone levels facilitates the onset of labor
45,57
. The fetus is able to 
metabolise placental progesterone in the production of adrenal steroids. 
 
A selective progesterone receptor modulator (SPRM) is an agent 
which acts on the progesterone receptor. A characteristic feature 
distinguishing such substances from progesterone (full agonists) and 
mifepristone (full antagonists) is that these exert different action in 
different tissues. This mixed agonist/antagonist profile of action leads to 
selective stimulation or inhibition of progesterone-like action in different 
tissues
60 
and raising the possibility of dissociation of desirable therapeutic 
effects from undesirable side effects in synthetic progesterone receptor 
drug candidates
61 
 
ER AND PR IN NORMAL ENDOMETRIUM 
62,63,64 
In the human uterus, the concentrations of receptors for both 
estrogen (ER) and progesterone (PR) undergo characteristic variations 
throughout the menstrual cycle in response to the hormonal change. 
 
The endometrium appears to express estrogen receptors (ER) and 
progesterone receptors (PR). There is difference in expression of the 
steroid receptors in the epithelial and the stromal cells indicating, the 
autocrine and paracrine regulation of cyclic functional and morphological 
changes in these cells.In the normal postmenopausal endometrial tissue, 
there is down-regulation of ER alpha, ER beta and PR-B with higher 
expression of PR-A. 
 
Steroid receptors ERalpha, ERbeta, PR-A and PR-B are expressed 
differently in normal and atrophic human endometrium which has been 
observed by Mylonas I, P. M. L. Snijder and many other groups
62,63,64 
 
During the menstrual cycle, there occurs a significant change in the 
estrogen receptor present in the glands and stroma of the endometrium 
basalis and functionalis and in smooth muscle cells of the myometrium. 
Mostly in all types of cells in the endometrium, estrogen receptor 
expression was found to be maximum in the late proliferative phase. 
 
The estrogen receptor staining sharply decreases during the early 
secretory phase of the endometrium in stromal and smooth muscle cells, 
while, in glandular epithelium, estrogen receptor expression aapears to 
decrease gradually
63
.There is increase in estrogen receptor in the 
predecudualising stromal cells and smooth muscle cells during the mid 
and late phases  of secretory endometrium. 
ER AND PR IN NEOPLASTIC ENDOMETRIUM 
Endometrial carcinoma is one of the most common gynecologic 
malignancies in industrialized and developing countries. Various 
prognostic factors have been extensively studied to improve the treatment 
and follow-up of these patients. 
 
Prognostic significance of steroid hormone receptors has been well 
established in breast cancer. Several studies on breast cancer have 
confirmed the validity of ER/PR immunohistochemical assay and have 
shown its prognostic and therapeutic usefulness. Analogous Studies in 
endometrial carcinoma are scanty and largely limited to clinoco-
pathological correlation. 
Patients suffering from advanced or recurrent endometrial 
carcinoma and having significant concentrations of both receptors in the 
tumor tend to have a more indolent clinical course than patients with 
absent or low tumor receptors. 
 
         Patients whose lesions are progestin receptor-rich respond to regular 
treatment than those with receptor-poor tumors. In contrast, patients with 
advanced or recurrent disease after regular treatment and with low tumor 
estrogen and progestin receptor concentrations respond more often to 
combination cytotoxic chemotherapy than patients with higher tumor 
receptor levels. 
 
Many studies have noted the influence of the steroid receptor 
content on survival. Geisinger et al. found that progestin-positive as well 
as quantitative level of the progestin receptor were significantly related to 
survival.  
 
Creasman et al.showed that estrogen receptor-positive status, 
progestin receptor-positive status,and combined estrogen receptor and 
progestin receptor-positive status had a significantly better disease-free 
survival than those with negative receptor status tumors.  
 
Myolonas I stated that the loss of receptor positivity for ER-alpha 
resulted in a poorer survival in endometrial cancer patients, while ER-
beta did not affect survival. 
 
IMPORTANCE OF p53 
 p53 is a tumour suppressor gene which is situated on  the 
chromosome 17p13.1. It is found to be the most frequent target for 
genetic alteration in human tumours65. p53 controls the neoplastic 
transformation by three interlocking mechanisms: 
a) Activating arrest of the temporary cell cycle  
b) Inducing arrest of the permanent cell cycle. 
c) Triggering the programmed cell death. 
Mutation of p53 were seen in 10% of all endometrioid carcinomas, 
with 50% occurring in grade 3 tumour and which were not  identified in 
grade I tumour or endometrial hyperplasia.  
In serous carcinomas about 90% of cases show p53 gene 
mutation53,54. In serous carcinomas p53 mutations occurs earlier which is 
the reason for its aggressive course. Since p53 mutation occurs in high 
grade endometrioid (type I) carcinomas and also in serous papillary 
carcinomas (type II), p53 is considered as an indicator of aggressive 
tumours
55
. 
KRAS and PTEN mutations are very rare in serous carcinomas. 
Microsatellite instability is not observed in the serous type
56
. Recently 
PIK3A mutation has been described in 15% of serous carcinomas 
indicating that PIK3A/PTEN/AKT pathway may have a role in the 
pathogenesis of a subset of the serous tumours.  
From the above discussion, it is understood that very little is 
known about the molecular pathogenesis of the two types of endometrial 
carcinomas. However from the studies so far conducted it is evident that 
endometrioid and serous carcinomas of the endometrium are two 
different entities, with distinct molecular pathways and prognosis.  
The current study has been undertaken to evaluate the steroid 
hormone receptor status and p53 status in endometrial carcinomas using 
immunohistochemical method and to assess its significance in disease 
progression. 
                      
                              
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
Materials and Methods 
  
MATERIALS AND METHODS 
STUDY PLACE: 
    Coimbatore Medical College and Hospital. 
STUDY DESIGN: 
The present cross-sectional study was a   prospective  study conducted in 
the Department of Pathology  on  “HISTOMORPHOLOGY AND ROLE 
OF IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL 
CARCINOMAS”  during the period of October 2012 to July 2014. The 
ethical clearance was obtained from the Ethical Committee of 
Coimbatore Medical College, Coimbatore. 
A sample of 30 cases of endometrial carcinomas were analysed 
during the period of October 2012- July 2014.  
 INCLUSION CRITERIA:  
        All specimens of endometrial carcinomas were received in the 
Department of Pathology, Coimbatore Medical College and Hospital, 
Coimbatore - 18                                                                                                                               
 
 
 
EXCLUSION CRITERIA 
1. Patients who received prior radiotherapy and chemotherapy. 
2.Illfixed  specimen 
3.Endocervical  carcinomas. 
COLLECTION OF DATA: 
     All the hysterectomy specimens sent to the Department of 
Pathology were included. Thorough history of the patients were recorded 
on predesigned and pretested proforma (Annexure I).  
 
METHODOLOGY AND TECHNIQUES  
The specimens were received in 10% formalin. The macroscopic 
features are noted and the tissue will be then processed routinely , 
paraffin sections were cut at  4 -5 micrometers thickness and stained with 
Haematoxylin and Eosin and were examined  by light microscopy. 
 
They are then  classified into Type l or Type ll based on their 
histomorphology. Then Immunohistochemistry study was done. For 
immunohistochemistry sections of 4 microns thickness are cut and then 
taken on coated slides(slides coated with gelatin chrome alum mixture) 
and incubated at 58 degrees overnight and these slides are used for 
running immunohistochemistry by a two step indirect technique. 
Immunohistochemical markers: 
The panel of markers used in the present study were ER,PR and p53. 
PROCEDURE OF IMMUNOHISTOCHEMISTRY 
METHOD :   Two step indirect technique. 
PRINCIPLE OF THE PROCEDURE 
The antigens that are present in tissues and cells are detected by 
two stage  process which is as follows: 
The binding of the primary antibody to specific epitopes and its 
subsequent  detection by a calorimetric reaction.  
Tissue sections which were taken on coated glass slides (coated 
with gelatin- chrome alum mixture) are incubated overnight at 37 
degrees. Antigen retrieval is done by heating the tissue sections in buffer  
solution in microwave. The buffer solution used are tris-EDTA and 
citrate buffer. In the present study ER, PR and P53 antigens were 
retrieved in tris EDTA which has a ph of 9. 
 
REAGENTS USED 
1. Peroxide block: 3% hydrogen peroxide in water. 
2. Power block reagent: It’s a protein blocking reagent containing 
casein and    propriety additives in PBS with 15Mm sodium azide.
  
3. Chromogen: DAB-3,3’-diaminobenzidine. 
4. Liquid DAB Substrate:Contains Tris buffer with the peroxide and 
stabilizers. 
5. Superenhancer reagent 
6. Poly-HRP Reagent 
7. Counter stain with Mayer’s Hematoxylin. 
8. Buffer solutions: 
 
TRIS EDTA : 
Distilled water – 1000 ml 
TRIS Buffer salt – 6.05 grams 
Disodium EDTA – 0.744 grams 
 
CITRATE BUFFER  : ( ph – 6) 
Distilled water – 1000 ml 
Trisodium citrate – 2.94 grams 
1N Hydrochloric acid 5 ml 
 
TRIS BUFFER : 
Distilled water 1000 ml 
TRIS Buffer salt – 0.605 grams  
Sodium chloride – 8 grams 
1 N Hydrochloric acid -3 ml 
 
 PROCEDURE 
1.  The sections are deparaffinised in xylene for 15 minutes in 2 
changes. 
2.  Washed in alcohol for 5minutes in 2 changes. 
3.  Washed in 50% alcohol for 5 minutes 
4.  Washed in running tap water for 5 minutes. 
5.  Then rinsed in distilled water for 5 minutes. 
6.  Next step is the antigen retrieval which is done by placing the 
slides with tris EDTA buffer solution in microwave:Medium - 5 
mins  for three times and then in High – 5 mins for two times. 
7.  It is then cooled to room temperature . 
8.  Then rinsed in distilled water. 
9.  Washed in TBS buffer for 5 minutes in 2 changes. 
10.  Treated with Peroxide block for 10 minutes. 
11.  Washed in TBS buffer for 5 minutes in 2 changes. 
12.  Treated with power block for 10 minutes. 
13.  Then the power block is drained and the sections are covered with 
primary antibody (BIOGENEX) for 2 hours.  
14.  Washed in TBS buffer for 5 minutes in 2 changes. 
15.  Then the slides are covered with Superenhancer for 30 minutes. 
16.  Washed in TBS buffer for 5 minutes in 2 changes. 
17.  Slides are then covered with SS label(HRP Polymer reagent) for 30 
minutes. 
18.  Washed in TBS buffer for 5 minutes in 2 changes. 
19.  The slides are then treated with 1ml of DAB buffer,1 drop of of 
peroxide block,4 drops of DAB chromogen for 5-8 minutes. The 
diaminobenzidine gives  brown colour to the antigen antibody 
reaction. This is carcinogenic and hence should be used with 
precautionary measures including wearing of gears like apron,mask 
and gloves. 
20.  Washed in TBS for 5 minutes in 2 changes. 
21.  Then the slides are washed in running tap water for 5 minutes. 
22.  Counterstaining is done with Ehrlich’s Hematoxylin for 30 
seconds. Then    washed in tap water for 5 minutes. 
23.  Sections are then air dried. 
24.  Slides are then mounted with DPX. 
Tumour cells are scored positive if there is golden brown 
cytoplasmic staining in the neoplastic cells. 
 
INTERPRETATION : 
ER, PR and p53 expression will be indicated by nuclear positivity 
in glandular cells. The positivity of both ER and PR were scored as the 
sum of the percentage of stained cells and intensity of nuclear staining. 
Based on the percentage of cells there are three grades 
Grade 1 – 0-25% of the nuclei stained. 
Grade II – 26-75% of the nuclei stained  
Grade III - >76%  of the nuclei stained  
Based on the staining intensity  
Grade I – absent or weak 
Grade II – strong 
Grade III -  very strong. 
The sum of both the parameters determine the score. 
Tumours were classified into three categories depending on the 
 immunohistochemistry score 
Category I – score of 2 indicates immunonegativity 
Category II – score of 3 or 4 indicates immnunopositivity 
Category III – score of 5 or 6 indicates immnunopositivity
100 
The most common distribution patterns of p53 were: 
a) diffuse (>70%) of intense nuclear staining. 
b) no staining or cytoplasmic staining only 
c) focal weak to intense staining of scattered neoplastic cells(<30%) 
d) complete absence of staining in all tumour cell nuclei 
e) abrupt transition from minimal to marked staining. 
 
 
 
 
 
  
 STATISTICAL ANALYSIS: 
The data was coded and entered into Microsoft excel spread sheet 
(Annexure II) and was analysed using ratios and percentage. Correlation 
between the histopathological results and immunohistochemistry results 
were calculated by using chi-square test.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Results 
  
                     RESULTS AND OBSERVATION 
Our present study was conducted in the Department of Pathology 
during the  period of October 2012 – July 2014 on 
“HISTOMORPHOLOGY AND ROLE  OF 
IMMUNOHISTOCHEMISTRY  IN ENDOMETRIAL 
CARCINOMAS”.  Ethical committee clearance was obtained from the 
Ethical Committee of  Coimbatore Medical College and Hospital, 
Coimbatore. 
   A total of 30 cases of endometrial carcinomas were studied during 
the  period. 
                                          
 
 
 
 
  
STATISTICS 
TABLE  : 1    
AGE WISE DISTRIBUTION OF ENDOMETRIAL CARCINOMAS 
IN THE PRESENT STUDY POPULATION 
AGE GROUP NUMBER OF 
PATIENTS 
PERCENTAGE 
40-49 years 08 26.66% 
50-59 years 10 33.33% 
60-69 years 10 33.33% 
70 years and above 02 6.66% 
 
Women in the age group in which endometrial carcinomas usually 
presented were those who were above 55 years. Most common age group 
according to the present  study is 50-69 years. Mean age according to the 
above study was 52.7 years. 
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TABLE :  2 
FREQUENCY OF PRESENTATION OF SYMPTOMS IN 
ENDOMETRIAL CARCINOMA IN THE STUDY 
   
SYMPTOMS 
NUMBER OF 
CASES 
PERCENTAGE 
Bleeding per vagina 18 60% 
Abdomen pain 06 20% 
Amenorrhea 04 13.33% 
Others 02 6.67% 
 
The most common presentation of endometrial carcinomas in the 
present study is bleeding per vagina comprising 60% followed by pain 
abdomen, amenorrhea, menorrhagia, mass per abdomen, difficulty in 
passing urine and mass per vagina. 
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TABLE  : 3 
THE DISTRIBUTION OF ENDOMETRIAL CARCINOMAS WITH 
RESPECT TO THE PERIOD OF REPRODUCTIVE LIFE 
 
STATUS NUMBER OF 
PATIENTS 
PERCENTAGE  
Premenopausal 07 23.33% 
Postmenopausal 23 76.66% 
 
Usually endometrial carcinomas are found to be distributed in 
postmenopausal age group which in the present study constitutes 76.66%, 
the remaining were found to be perimenopausal and premenopausal 
comprising 23.33%.  
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TABLE  : 4 
 THE DEPTH OF INVASION OF ENDOMETRIAL CARCINOMA 
IN THE PRESENT STUDY 
 
MYOMETRIAL 
INVASION 
NUMBER OF 
PATIENTS 
PERCENTAGE 
Less than half of 
myometrium 
18 60% 
More than half of 
myometrium 
12 40% 
 
The depth of invasion of endometrial carcinomas were illustrated 
as above and it was found that in the present study, endometrial 
carcinomas usually were found confined to less than half of the 
myometrium or there was minimal involvement of the myometrium in 
around 60% of the cases. About 40% of the cases showed more than half 
of the myometrial invasion. 
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 TABLE : 5 
THE DISTRIBUTION OF HISTOLOGIC TYPES IN 
ENDOMETRIAL CARCINOMA IN THE PRESENT STUDY 
HISTOLOGIC TYPE 
NUMBER OF 
CASES 
PERCENTAGE 
Type I carcinoma 16 53.33% 
Type II carcinoma 14 46.66% 
 
In the present study, type I constituted 53.33% which is the most 
common histologic type among endometrial carcinomas and 46.66% 
were among type II.  
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TABLE : 6  
 
HISTOLOGIC TYPES IN ENDOMETRIAL CARCINOMA TYPE I 
 
HISTOLOGIC TYPE NUMBER OF 
CASES 
PERCENTAGE 
Well differentiated grade 
 
endometrioid 
8 50% 
Moderately differentiated 
grade 
endometrioid 
6 37.5% 
Higher grade 
endometrioid 
2 12.5% 
 
In the present study,16 cases of type I endometrioid tumors were studied. 
Among the sixteen cases, well differentiated endometrioid constituted 
50%, moderately differentiated endometrioid tumors constituted 37.5% 
and higher grade endometrioid constituted 12.5%. 
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TABLE 7 
HISTOLOGIC TYPES OF ENDOMETRIAL CARCINOMA TYPE 
II 
HISTOLOGIC TYPE NUMBER OF 
CASES 
PERCENTAGE 
Uterine  papillary serous 
carcinoma 
8 57.14% 
Clear cell carcinoma 6 42.86% 
 
In the study, fourteen cases of type II carcinomas were studied. Among 
the fourteen cases, 57.14% were uterine papillary serous carcinomas and 
42.86% were clear cell carcinomas. 
 
  
HISTOLOGIC TYPES OF ENDOMETRIAL CARCINOMA TYPE 
 
8
0
1
2
3
4
5
6
7
8
9
Uterine  papillary serous carcinoma
Histologic types of type II carcinomas
CHART : 7 
II 
 
 
 
6
Clear cell carcinoma
 
Series 1
TABLE :  8 
 THE DISTRIBUTION OF ARCHITECTURAL GRADING IN 
ENDOMETRIAL CARCINOMA 
 
ARCHITECTURE 
NUMBER OF 
CASES 
PERCENTAGE 
Glandular pattern 09 30% 
Glandular admixed with 
sheets 
12 40% 
Sheet 08 26.67% 
Papillary pattern 01 3.33% 
 
Most common architectural pattern in the present study is glands 
and sheets comprising 40%, next in the grading were tumours composed 
entirely of glands consisting of 30% and then 26.67 % of the tumours 
were entirely composed of sheets / solid pattern. 
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TABLE  : 9 
THE EXPRESSION OF ESTROGEN RECEPTOR IN TYPE  I AND 
TYPE II ENDOMETRIAL CARCINOMAS 
EXPRESSION OF 
ESTROGEN 
RECEPTOR 
NUMBER 
(PERCENTAGE)  
OF POSITIVE 
CASES 
NUMBER 
(PERCENTAGE) 
OF NEGATIVE 
CASES 
Type I 13 (81.25%) 03 (18.75%) 
Type II 03 (21.43%) 11 (78.57%) 
 
In the present study, out of 16 cases in type I -13 cases were 
positive constituting 81.25% and 3 cases were negative comprising 
18.75% and out of 14 cases of type II – 3 were positive constituting 
21.43% and 11 cases were negative comprising 78.57%. 
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THE EXPRESSION OF PROGESTERONE RECEPTOR IN TYPE 
I AND TYPE II ENDOMETRIAL CARCINOMAS 
 
EXPRESSSION OF 
PROGESTERONE 
RECEPTOR 
NUMBER 
(PERCENTAGE) 
OF POSITIVE 
CASES 
NUMBER 
(PERCENTAGE) 
OF NEGATIVE 
CASES 
Type I 12 (75%) 04 (25%) 
Type II 04 (28.75%) 10 (71.42%) 
 
In the above study out of 16 cases in type I - 12 cases were positive 
constituting 75% and 4 cases were negative constituting 25% and out of 
14 cases of type II - 4 cases were positive comprising 28.75% and 10 
cases were negative constituting 71.42%. 
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TABLE : 11 
THE EXPRESSION OF p53 IN TYPE I AND TYPE II 
ENDOMETRIAL CARCINOMAS 
 
EXPRESSION 
OF p53 
NUMBER 
(PERCENTAGE) 
OF POSITIVE  
CASES 
NUMBER 
(PERCENTAGE) 
OF NEGATIVE 
CASES 
Type I 07 (43.75 %) 09 (56.25%) 
Type II 11 (78.57%) 03 (21.43%) 
 
In the present study out of 16 cases in type I – 7 cases were 
positive constituting 43.75% and 9 cases were negative which constitutes 
56.25%, and out of 14 cases of type II – 11 cases were positive 
comprising 78.57%  and 3 were negative constituting 21.43%. 
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TABLE  : 12 
THE EXPRESSION OF ESTROGEN RECEPTOR IN TYPE I AND 
TYPE II ENDOMETRIAL CARCINOMAS BY 
IMMUNOHISTOCHEMICAL SCORE 
 
 
 
NEGATIVE  POSITIVE 
Total 
Category 1 Category 2 Category 3 
Type I 03 05 08 
16 
Type II 11 02 01 
14 
 
The association of histologic types with estrogen receptor was 
tested using chi-square analysis,the value was found to be 10.75 with the 
p value less than 0.01(significant at 1% level) which implies a significant 
association between the type I carcinoma and expression of estrogen 
receptor. 
The positivity of both ER and PR were scored as the sum of the 
percentage of stained cells and intensity of nuclear staining. 
Based on the percentage of cells there are three grades 
Grade 1 – 0-25% of the nuclei stained. 
Grade II – 26-75% of the nuclei stained  
Grade III - >76%  of the nuclei stained  
Based on the staining intensity  
Grade I – absent or weak 
Grade II – strong 
Grade III -  very strong. 
The sum of both the parameters determine the score. 
Tumours were classified into three categories depending on the 
 immunohistochemistry score 
Category I – score of 2 indicates immunonegativity 
Category II – score of 3 or 4 indicates immnunopositivity 
Category III – score of 5 or 6 indicates immnunopositivity
76 
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 TABLE : 13 
EXPRESSION OF PROGESTERONE RECEPTOR IN TYPE I  
AND TYPE II ENDOMETRIAL CARCINOMAS BY 
IMMUNOHISTOCHEMICAL SCORE 
 
 
 
NEGATIVE  POSITIVE 
Total 
Category 1 Category 2 Category 3 
Type I 04 05 07 16 
Type II 10 02 02 14 
 
 
 The association of histologic types with progesterone receptor was 
tested using chi-square analysis,the value was found to be 6.53 with the p 
value less than 0.05(significant at 5% level) which implies a significant 
association between the type I carcinoma and expression of progesterone 
receptor 
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TABLE :  14 
EXPRESSION OF p53 IN TYPE I AND TYPE II 
ENDOMETRIAL CARCINOMA BY 
IMMUNOHISTOCHEMISTRY 
 
 
 
NEGATIVE  POSITIVE  
Total 
Negative <30% 30-70% >70% 
Type I 9 2 2 3 16 
Type II 3 2 4 5 14 
 
 The association of histologic types with p53 was tested using chi-
square analysis,the value was found to be 3.77 with the p value less than 
0.05(significant at 5% level) which implies a significant association 
between the type II carcinoma and expression of p53.  
 The most common distribution patterns of p53 were: 
a) diffuse (>70%) of intense nuclear staining. 
b) no staining or cytoplasmic staining only 
c) focal weak to intense staining of scattered neoplastic cells(<30%) 
d) complete absence of staining in all tumour cell nuclei 
e) abrupt transition from minimal to marked staining. 
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Figure 3 : Gross picture of endometrial carcinoma of uterus showing 
a proliferative growth filling the entire endometrial cavity and 
extending upto the serosa. 
 
 
 
 
 
 
                     : 
 
Figure 4 :  H& E  shows  well differentiated endometrioid 
 
Figure 5: H & E shows papillary serous carcinoma (40
carcinoma (10 X) 
 
 
 
 X) 
Figure 6 : H
Figure 7 : H & E showing mucinous type of endometrial 
 & E showing clear cell carcinoma (40 X)
carcinoma(10 X) 
 
 
 
Figure 8 : H & 
by endometrioid carcinoma(10 X)
Figure 9: Immunohistochemistry showing 
E showing involvement of the cervical canal 
 
 
ER expression
 
 
 
,  
Category 2 in type I carcinoma (10 X) 
 
Figure 10: Immunohistochemistry showing nuclear staining  
of ER Category 3 in type I carcinoma (100 X) 
 
    
Figure 11 : Immunohistochemistry showing ER negative in  
type II carcinoma (40 X) 
 
Figure 12 : Immunohistochemistry showing positive nuclear  
staining of PR Category 3 in type I carcinoma (10 X) 
 
 
Figure 13 : Immunohistochemistry showing  nuclear staining of  PR 
in type I carcinomas. Category 2 (40 X) 
 
Figure 14: Immunohistochemistry showing nuclear positivity  
for p53 (>70% staining) (10 X) 
 
Figure 15 : Immunohistochemistry showing nuclear positivity
p53 in type II carcinomas
Figure 16 : Immunohistochemistry showing p53 nuclear positivity
in type II carcinoma
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Discussion 
  
DISCUSSION 
 
The endometrial carcinomas are class of neoplasms in which 
pathologic factors play an important role in determining the prognosis of 
the patient. Basically endometrial carcinomas are of two types: type I- 
estrogen dependent tumors and type II – non estrogen dependent tumors.  
 
Type I are usually seen in premenopausal and perimenopausal 
women in patients with hyperplastic endometrium, usually does not 
involve the myometrium. Most of them are well to moderately 
differentiated and rarely presents with distant metastasis and hence 
usually have a better prognosis. 
 
 Whereas type II tumours, occur in females little older than the 
estrogen dependent type. They are usually of higher grades and presents 
with distant metastasis and are associated with poor prognosis.  
 
There are few well established prognostic factors which includes, 
stage of the tumor, grade of the tumor and the depth of invasion of the 
myometrium. 
 
 Recently nuclear grade of the tumor and vascular invasion of the 
tumor were also recognized as important prognostic factors. 
The advent of immunohistochemistry proved to be of significance 
in many malignancies like the breast, soft tissue tumours etc., to arrive at 
a diagnosis and were helpful in assessing the prognosis and in the 
management of the patients. 
 
There are numerous studies showing inverse correlation between 
the steroid hormone receptor status and the grade of the tumour and direct 
relationship of p53 positivity with higher grade of tumours. 
 
In the present study: A total of 30 cases of endometrial carcinomas 
were studied histologically and the immunohistochemistry expression for 
ER, PR and p53 were correlated. Among the thirty cases sixteen were 
type I and fourteen were type II.  
 
  Expression of ER: Out of 16 cases in type I -13 cases were 
positive and 3 cases were negative and out of 14 cases of type II – 3 cases 
were positive cases and 11 cases were negative. 
 
Expression of PR: Out of 16 cases in type I - 12 cases were 
positive and 4 cases were negative and out of 14 cases of type II - 4 cases 
were positive and 10 cases were negative. 
Expression of p53: Out of 16 cases in type I – 7 cases were 
positive and 9 cases were negative and out of 14 cases of type II – 11 
cases were positive and 3 were negative.  
 
In the present study women in the age group in which endometrial 
carcinomas usually presented were those who were above 55 years. Most 
common age group according to the present study is 50-69 years. Mean 
age according to the above study was 52.7 years. 
 
According to G. Plataniotis and Castiglione
66
 the median age of 
occurrence is 63 years and more than 90% of women were found to be 
older than 50. 
 
The most common presentation of endometrial carcinomas in our 
present study was bleeding per vagina comprising 60% followed by pain 
abdomen, amenorrhea, menorrhagia, mass per abdomen, difficulty in 
passing urine and mass per vagina. 
 
Usually endometrial carcinomas are found to be distributed in 
postmenopausal age group which in the present study constitutes 76.66%, 
the remaining were found to be perimenopausal and premenopausal 
comprising 23.33%. 
The depth of invasion of endometrial carcinomas in the present 
study, were usually found confined to less than half of the myometrium 
or there was minimal involvement of the myometrium in around 60% of 
the cases. About 40% of the cases showed more than half of the 
myometrium showing invasion. 
 
In the present study, among the various histologic types, type I 
constituted 53.33% of endometrial carcinomas and 46.66% were  type II  
carcinomas. 
 
In the present study, 16 cases of type I endometrioid tumors were 
studied. Among the sixteen cases, well differentiated endometrioid 
constituted 50%, moderately differentiated endometrioid tumors 
constituted 37.5% and higher grade endometrioid constituted 12.5%. 
 
In the study, fourteen cases of type II carcinomas were studied. 
Among the fourteen cases, 57.14% were uterine papillary serous 
carcinomas and 42.86% were clear cell carcinomas. 
 
Most common architectural pattern in the present study is glands 
and sheets comprising 40% next were tumours composed entirely of 
glands consisting of 30% and then 26.67% of tumours were entirely 
composed of sheets or solid pattern. 
In the present study, expression of ER was determined by the 
immunohistochemical score. A total of 16 cases were evaluated in type I 
carcinomas – in which 13 cases were found to be positive comprising of  
81.25% (which included weakly positive and strongly positive cases) and 
3 cases were found to be  negative constituting 18.75% and among the 13 
positive cases, five of them were weakly positive categorized as category 
two and eight were strongly positive categorized under category three. 
Whereas among  the 14 cases of type II (higher grade, serous papillary 
carcinomas and clear cell carcinomas)  3 positive cases consisting of 
21.43 %, two were weakly positive and one was strongly positive and 11 
cases were negative comprising 78.57%. 
 
As per Sidonia Catalina Stoian
70
 et al a retrospective analysis on 
endometrial carcinomas , ER positivity was seen in 86.3% of type I 
tumors and 13.4% of the type I tumors cases  were found to be negative 
for ER. 
 
The association of histologic types with estrogen receptor was 
tested using chi-square analysis, the value was found to be 10.75 with the 
p value less than 0.01 (significant at 1% level) which implies a significant 
association exist between the type I carcinoma and expression of estrogen 
receptor. 
 
In the given study, the expression of PR was determined by the 
immunohistochemical score. A total of 16 cases were evaluated in type I 
endometrioid carcinomas – in which 12 cases were found to be positive 
comprising of  75% (includes weakly positive and strongly positive 
cases) among which five cases were weakly positive and seven cases 
were strongly positive and 4 cases were found to be  negative constituting 
25%. Whereas among the 14 cases of type II (higher grade, serous 
papillary carcinomas and clear cell carcinomas) 4 cases were positive 
comprising of   28.75% (among them two were weakly positive and two 
was strongly positive) and 10 cases were negative comprising 71.42%. 
 
Sidonia Catalina Stoian70 et al  analysed 22 cases retrospectively 
and  observed  81.1% of type I tumors to be positive for PR while 18.9% 
of type I tumors were reported to be negative. 
 
The association of histologic types with progesterone receptor was 
tested using chi-square analysis,the value was found to be 6.53 with the p 
value less than 0.05 (significant at 5%  level) which implies a significant 
association exist between the type I carcinoma and expression of 
progesterone receptor. 
 Expression of p53: In the present study, from a total of 16 cases in 
type I (endometrioid type) – 7 cases were positive constituting 43.75%, 
among them two cases stained less than 30%, two cases stained 30-70% 
and three cases stained more than 70% and 9 cases were negative 
comprising about 56.25%, while in type II a total of 14 cases were 
evaluated –in which 11 cases were positive comprising 78.57% , in which 
two cases stained less than 30%, four cases stained 30-70% and five cases 
stained more than 70% and 3 were negative constituting 21.43%.  
 
          The association of histologic types with p53 was tested using chi-
square analysis,the value was found to be 3.77 with the p value less than 
0.05 (significant at 5% level) which implies a significant association 
between the type II carcinoma and expression of p53.  
 
A study conducted by Nicola Ragina
69
 et al, on 240 specimens of 
endometrial carcinomas showed that nearly 100 % of the uterine papillary 
serous tumors  (type II) were positive for p53 when compared to 60% of 
the endometrioid tumors (type I). There was a trend for immunopositivity 
in advanced stage tumors constituting 86.2% while compared to 64.3% in 
early stage tumors. Positive p53staining was observed in 111 of the 182 
(61%) endometrioid tumors  (type I) and in 47 of the 58 (81.0%) type II. 
p53 expression was significantly higher in papillary serous carcinomas 
(type II) than in the endometrioid type (type I). 
 
 
Recent reports suggest that ER, PR and p53status, as determined 
by immunohistochemical studies, can be used as an independent predictor 
for disease recurrence also. The numbers in this study were too small to 
make a definitive statement on the importance of hormone receptors and 
p53 to predict the recurrence of the disease. 
                
  
  
 
 
 
 
 
 
 
 
 
 
Summary 
  
SUMMARY OF THE STUDY 
 
The present study is a cross sectional prospective study on 
endometrial carcinomas. A sample of  30 specimens were collected and 
studied during this period. 
 
The following were observed in the course of this study: 
 
1. The incidence of endometrial carcinomas in our hospital was found 
to be 1.73% 
 
2. The mean age of the patients diagnosed with endometrial 
carcinomas was 52 years. 
 
3. 60% of the patients were postmenopausal. 
 
4. Around 60% of the cases showed no involvement or less than than 
half of the thickness of the myometrium showing involvement by 
the tumor. 
 
5.  Of the 30 samples studied, 53.33% were type I tumours and 
46.66% were type II tumors. 
 
 
 
6. In the present study, 16 cases of type I endometrioid tumors were 
studied. Among the sixteen cases, well differentiated endometrioid 
constituted 50%, moderately differentiated endometrioid tumors 
constituted 37.5% and higher grade endometrioid constituted 
12.5%. 
 
7. In the study, fourteen cases of type II carcinomas were studied. 
Among the fourteen cases, 57.14% were uterine papillary serous 
carcinomas and 42.86% were clear cell carcinomas. 
 
8. The most common architectural pattern was tumour cells in glands 
and sheets forming around 40% of the total tumours followed by 
tumour cells arranged in glandular pattern comprising 30%, tumour 
cells in sheets forming 26.6% and the remaining cases forming 
papillary pattern.  
 
9. The expression of ER in type I carcinomas were 81.25% and in 
type II tumors 21.43% of cases showed ER positivity. It was found 
that there was a positive correlation between the expression of ER 
and type I tumors. 
 
 
 
10. The expression of  PR in type I carcinomas were 75% and in type 
II tumors 28.75% of the cases showed PR positivity. In the present 
study there was a positive correlation between the expression of PR 
and type I tumors. 
 
11. The expression of p53 in type I carcinomas were 43.75% and in 
type II tumors 78.57% of the cases showed p53 positivity. In the 
present study there was positive correlation between the type II 
endometrial carcinomas and p53 expression. 
 
The immunohistochemical study of ER, PR and p53 and its 
significance on the prognosis are few in literature when compared to 
breast carcinoma. Our data will be definitely an important addition to the 
existing literature and this has to be standardized by further studies. 
 
  
FURTHER STUDIES 
 
1.  The patients with endometrial carcinomas after surgery have to be 
followed up along with the immunohistochemical status of ER, PR 
and p53 for assessing the prognosis and to standardize treatment 
protocols.  
2.  Expression of additional immunohistochemical markers have to  be 
studied and its implication in the treatment and prognosis  of 
endometrial carcinomas have to be standarised. 
3.  Based on the above criteria, follow up protocol and management 
strategies can be standardized. 
4.  The patients has to be divided into type I and type II, since the type 
I carcinomas are managed by hysterectomy and hormonal therapy 
and type II carcinomas are managed by surgery along with 
chemotherapy and radiotherapy. Further studies with more number 
of patients are required. 
5.  Novel markers like expression of ER and PR for type I carcinomas 
and expression of p53, p16 for type II carcinomas can be made 
available and their utility for choosing treatment and predicting 
prognosis has to be standardized. 
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Annexur-I 
  
ANNEXURE I - PROFORMA 
Department of Pathology 
Coimbatore Medical College 
Coimbatore 
 
Patientt’s name: 
Age/Sex 
IP No 
Occupation 
Income 
Address 
HPE No. 
PRESENTING ILLNESS: 
History of presenting illness 
History of bleeding: Amount- Heavy/moderate/scant 
                                  Duration 
History of dusmenorrhea 
History of white discharge 
OBSTETRIC HISTORY 
Married since ………….. years 
Para:…………………….History of abortions 
Last child birth: 
Sterilisation history: 
MENSTRUAL HISTORY 
Age at menarchy 
Menstrual cycle:regular/ irregular,Duration 
Amount of bleeding 
PERSONAL HISTORY 
Diet history 
Appetite 
Bladder and bowel habits 
PAST HISTORY 
History of diabetes/hypertension 
History of any other major illness 
History of drug intake 
GENERAL EXAMINATION 
Built and nourishment 
Pallor/icterus/lymphadenopathy 
Pulse 
Blood pressure 
SYSTEMIC EXAMINATION 
Cardiovascular system 
Respiratory  system 
Per abdomen: Liver- palpable/normal 
                       Spleen- palpable/normal 
Central nervous system 
LOCAL EXAMINATION 
Speculum examination 
Vulva: Healthy/unhealthy 
Vagina 
Cervix 
Vaginal examination 
Cervix: Direction 
             Consistency 
              Bleeds on touch 
              Cervical erosion 
Uterus: Anteverted/Retroverted 
             Normal/bulky/small. 
             Mobile/fixed 
LABORATORY EXAMINATION 
1.URINE: Albumin 
        Sugar 
        Microscopy 
2.HAEMATOLOGY 
Haemoglobin………….gms% 
RBC :……………..millions/cumm 
WBC count:……………/cumm 
PCV:………% 
MCV………..% 
MCH:………% 
MCHC:………%Differential count:………./cumm 
ESR:……..mm/hr 
Blood group and RH type: 
Bleeding time… 
Clotting time 
Peripheral smear 
3.BIOCHEMICAL TEST 
Blood glucose:…..mg/dl 
Blood urea:……mg/dl 
Serum creatinine:…..mg/dl 
4.RADIOLOGICAL INVESSTIGATION: 
Ultrasound findings 
Others: 
BIOPSY AND HYSTERECTOMY SPECIMEN: 
Biopsy  
Gross appearance 
Microscopy 
Hysterectomy specimens 
Gross appearance: Size of the specimen 
   Size of the growth 
   Proliferative/Irregular/Polypoidal/Infiltrative growth 
   Myometrial involvement.Serosal involvement 
   Cervical involvement, Isthmic involvement 
   Parametrial involvement, Vaginal cuff involvement 
   Lymph Node status 
 
  
 
 
 
 
 
 
 
 
 
Annexure - II 
  
ANNEXURE II- MASTER CHART 
S.NO AGE I.P NO HISTOPATHOLOGY 
NO 
DIAGNOSIS HISTOPATHOLOGIC  
TYPE 
HISTOLOGIC 
TYPE 
ER PR P53 
1 53/F 465 G65 DUB I H.G.E NEGATIVE NEGATIVE POSTIVE 
2 65/F 71940 G177 DUB I WDE POSTIVE POSTIVE NEGATIVE 
3 55/F 6325 G332 PAIN ABDOMEN II UPSC NEGATIVE NEGATIVE POSTIVE 
4 52/F 17474 G367 DUB II UPSC NEGATIVE NEGATIVE POSTIVE 
5 37/F 38847 G394 DUB I MDE POSTIVE POSTIVE NEGATIVE 
6 42/F 47084 G497 DUB II CC POSTIVE NEGATIVE POSTIVE 
7 42/F 50724 G538 PAIN ABDOMEN I MDE POSTIVE POSTIVE POSTIVE 
8 55/F 52648 G544 DUB I MDE POSTIVE POSTIVE NEGATIVE 
9 52/F 74411 G995 DUB II CC NEGATIVE NEGATIVE POSTIVE 
10 60/F 15976 G1287 PAIN ABDOMEN II CC NEGATIVE NEGATIVE POSTIVE 
11 45/F 56728 G1288 PAIN ABDOMEN I H.G.E NEGATIVE NEGATIVE POSTIVE 
12 60/F 16728 G1324 DUB II CC NEGATIVE NEGATIVE NEGATIVE 
13 45/F 24432 G1809 DUB II UPSC POSTIVE POSTIVE POSTIVE 
14 60/F 568299 P752 DIFFICULTY IN 
PASSING URINE 
I MDE POSTIVE NEGATIVE POSTIVE 
15 60/F 17300 G603 DUB II UPSC NEGATIVE NEGATIVE POSTIVE 
 
 
16 60/F 22669 G632 AMENORRHEA I WDE POSTIVE POSTIVE NEGATIVE 
17 54/F 804879 G1811 DUB II UPSC NEGATIVE NEGATIVE POSTIVE 
18 43/F 7654235 P1100 AMENORRHEA I WDE POSTIVE POSTIVE NEGATIVE 
19 50/F 765 E514 DUB II UPSC NEGATIVE POSTIVE POSTIVE 
20 48/F 588921 P146/14 DUB I WDE POSTIVE POSTIVE NEGATIVE 
21 77/F 57161 P665 PAIN ABDOMEN II CC NEGATIVE NEGATIVE POSTIVE 
22 50/F 568292 P624 DUB I MDE POSTIVE POSTIVE POSTIVE 
23 55/F 58648 G803 PAIN ABDOMEN I WDE NEGATIVE POSTIVE POSTIVE 
24 62/F 599766 P559 DUB I WDE POSTIVE NEGATIVE NEGATIVE 
25 60/F 66662 MLC283 AMENORRHEA II UPSC NEGATIVE POSTIVE POSTIVE 
26 60/F 57055 G105/14 DUB I WDE POSTIVE POSTIVE NEGATIVE 
27 60/F 27321 G1871 DUB I WDE POSTIVE POSTIVE NEGATIVE 
28 50/F 37205 G1164 PAIN ABDOMEN II UPSC POSTIVE POSTIVE NEGATIVE 
29 70/F 44035 G1298 DUB I MDE POSTIVE POSTIVE POSTIVE 
30 48/F 47835 G1814 AMENORRHEA II CC NEGATIVE NEGATIVE NEGATIVE 
 
  
ABBREVIATIONS FOR MASTERCHART 
 
WDE  - WELL DIFFERENTIATED ENDOMETRIOID 
MDE  - MODERATELY DIFFERENTIATED ENDOMETRIOID 
HGE  - HIGHER GRADE ENDOMETRIOID 
UPSC - UTERINE PAPILLARY SEROUS CARCINOMA 
CCC  - CLEARCELL CARCINOMA 
ER  - ESTROGEN RECEPTOR 
PR  - PROGESTERONE RECEPTOR 
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ANNEXURE III 
 
ABBREVIATIONS 
 
ER  - ESTROGEN RECEPTOR 
PR  - PROGESTERONE RECEPTOR 
CEA  - CARCINOEMBRYONIC ANTIGEN 
EIN  - ENDOMETRIAL INTRAEPITHELIAL  
NEOPLASIA 
CK  - CYTOKERATIN  
